The brief
- Established global pharma company; operations in roughly 80 countries; R&D in GI, rare disease, plasma, oncology.
- Zasocitinib designed using physics-based computational modeling; Takeda acquired Nimbus Therapeutics, which co-developed the drug.
- FDA Priority Review accepted Sep 2026 for plaque psoriasis; ~70% skin clear in Phase 3 at week 16.
Technical approach
Design
Physics-based computational chemistry
Computational modeling of how molecules bind and inhibit TYK2; avoids trial-and-error synthesis.
Target
Selective TYK2 inhibitor
Highly selective, potent TYK2 inhibitor disrupting the JAK-STAT autoimmune pathway.
Delivery
Once-daily oral pill
Small-molecule, oral once-daily formulation; better convenience than biologic infusions.
Efficacy
Rapid skin clearance
Phase 3: ~70% achieved clear skin by week 16; better than placebo and apremilast.
